HARP stock leaves Nasdaq after Merck completes USD 680 million takeover

HARP stock ceased trading after Merck completed its acquisition of Harpoon Therapeutics, Inc., a transaction valued at USD 680 million. The former Nasdaq-listed biotechnology company became a wholly owned Merck subsidiary on March 11, 2024, making the takeover the decisive fact for investors assessing the ticker in September 2026.

Merck completes the takeover

According to Life Sciences Pennsylvania, Merck completed the acquisition on March 11, 2024. The announcement identified Harpoon as a Nasdaq company and stated that its common stock would no longer be publicly traded or listed on the Nasdaq Stock Market.

Guavy reported on September 24, 2026, that Harpoon had exited Nasdaq following the transaction. The report puts the deal value at USD 680 million and describes Harpoon as a clinical-stage immunotherapy company rather than an independent listed issuer.

Cash terms define the final value

The completed merger converted each Harpoon common share into USD 23.00 in cash, according to Edgepedia. That per-share consideration and the USD 680 million equity value describe the same outcome from two different angles: a fixed cash settlement for holders and a strategic purchase price for Merck.

The transaction also ended Harpoon's standalone reporting cycle. Historical financial figures belong to the period before the March 11, 2024 closing, while later corporate developments sit within Merck's consolidated business rather than a separately traded HARP security.

HPN328 moves into oncology

Merck acquired Harpoon's TriTAC technology and its lead program HPN328, which is also known as MK-6070. The asset targets delta-like ligand 3, or DLL3, to direct immune cells toward cancer cells, giving the deal a pipeline rationale beyond the stock transaction.

For investors, the central comparison is clear: HARP's last independent share value was fixed at USD 23.00 in cash, while the broader transaction carried a USD 680 million valuation. The relevant exposure now belongs to Merck rather than to a separately quoted Harpoon share.

HARP stock is no longer listed

Harpoon's common stock ceased trading and listing on Nasdaq on March 11, 2024, as stated by Life Sciences Pennsylvania. The former ticker HARP therefore represents a completed corporate transaction, not an active standalone Nasdaq listing.

More news and analyses on HARP stock